Ekso Bionics announced that the Pricing, Data Analysis, and Coding contractor for the Centers for Medicare & Medicaid, CMS, Services has determined a final payment level of $91,031.93 for Medicare reimbursement of the Ekso Indego Personal, which took effect on April 1, 2024. Ekso Bionics will work with inpatient and outpatient clinics across the country to qualify individuals with spinal cord injuries who can potentially benefit from the Ekso Indego Personal. “There are clinically demonstrated advantages for individuals with SCI who train with Ekso’s Indego Personal device in post-acute care that help improve their quality of life,” said Jenna Tosto-Mancuso, PT, DPT, NCS, Clinical Manager, Division of Rehabilitation Innovation at Mount Sinai. “As patients can now benefit from reimbursement, those covered by CMS will gain improved access to this life changing device, which has the ability to accelerate their recovery outside of in-clinic or hospital rehabilitation and allow for better mobility in everyday life, which has associated mental health benefits.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKSO:
- Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
- Ekso Bionics price target lowered to $9.25 from $10 at H.C. Wainwright
- Ekso Bionics Reports Record Annual Revenue of $18.3 Million
- Is EKSO a Buy, Before Earnings?